argenx (NASDAQ:ARGX) had its price objective lifted by Wedbush from $130.00 to $131.00 in a report issued on Tuesday morning, Marketbeat.com reports. The firm currently has an outperform rating on the stock. Wedbush also issued estimates for argenx’s Q4 2018 earnings at ($0.82) EPS, FY2018 earnings at ($1.91) EPS, FY2019 earnings at ($2.94) EPS, FY2020 earnings at ($5.15) EPS, FY2021 earnings at ($4.66) EPS and FY2022 earnings at $5.54 EPS.
A number of other analysts have also recently weighed in on ARGX. Stifel Nicolaus initiated coverage on argenx in a research report on Thursday, September 13th. They set a buy rating and a $139.00 price target on the stock. Piper Jaffray Companies restated an overweight rating and issued a $154.00 target price on shares of argenx in a research report on Monday, September 17th. JMP Securities raised their target price on argenx to $150.00 and gave the company an outperform rating in a research report on Monday, September 17th. SunTrust Banks raised their target price on argenx to $132.00 and gave the company an in-line rating in a research report on Tuesday, September 18th. Finally, Evercore ISI assumed coverage on argenx in a research report on Monday, October 15th. They issued an outperform rating and a $110.00 target price on the stock. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $136.00.
Shares of argenx stock opened at $101.61 on Tuesday. argenx has a twelve month low of $29.33 and a twelve month high of $111.43.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Northern Trust Corp increased its position in argenx by 11.5% in the 2nd quarter. Northern Trust Corp now owns 12,418 shares of the company’s stock valued at $1,029,000 after acquiring an additional 1,285 shares during the period. Dimensional Fund Advisors LP increased its position in argenx by 22.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 7,559 shares of the company’s stock valued at $626,000 after acquiring an additional 1,366 shares during the period. Capital Fund Management S.A. acquired a new stake in argenx in the 3rd quarter valued at approximately $212,000. Stevens Capital Management LP acquired a new stake in argenx in the 3rd quarter valued at approximately $214,000. Finally, TD Asset Management Inc. increased its position in argenx by 8.2% in the 2nd quarter. TD Asset Management Inc. now owns 38,832 shares of the company’s stock valued at $3,218,000 after acquiring an additional 2,952 shares during the period. Hedge funds and other institutional investors own 64.40% of the company’s stock.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
See Also: Yield Curve
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.